Myocardial oxygen handling and metabolic function of ex-situ perfused human hearts from circulatory death donors

Background: This study investigated oxygen handling of human hearts donated after circulatory death (DCD) on normothermic ex-situ heart perfusion (ESHP) and evaluated oxygen handling markers as adjuncts to cardiac viability assessment. Methods: This single-center retrospective study included human D...

Full description

Saved in:
Bibliographic Details
Main Authors: Jorik H. Amesz, MSc, Sanne J.J. Langmuur, BSc, Mark F.A. Bierhuizen, MD, LLM, Dwight Dumay, BSc, Pieter C. van de Woestijne, MD, Jelena Sjatskig, MD, Lisa E. Sluijter, MSc, Dirk J. Duncker, MD, PhD, Olivier C. Manintveld, MD, PhD, Yannick J.H.J. Taverne, MD, PhD, MSc
Format: Article
Language:English
Published: Elsevier 2024-11-01
Series:JHLT Open
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2950133424001083
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850199105636139008
author Jorik H. Amesz, MSc
Sanne J.J. Langmuur, BSc
Mark F.A. Bierhuizen, MD, LLM
Dwight Dumay, BSc
Pieter C. van de Woestijne, MD
Jelena Sjatskig, MD
Lisa E. Sluijter, MSc
Dirk J. Duncker, MD, PhD
Olivier C. Manintveld, MD, PhD
Yannick J.H.J. Taverne, MD, PhD, MSc
author_facet Jorik H. Amesz, MSc
Sanne J.J. Langmuur, BSc
Mark F.A. Bierhuizen, MD, LLM
Dwight Dumay, BSc
Pieter C. van de Woestijne, MD
Jelena Sjatskig, MD
Lisa E. Sluijter, MSc
Dirk J. Duncker, MD, PhD
Olivier C. Manintveld, MD, PhD
Yannick J.H.J. Taverne, MD, PhD, MSc
author_sort Jorik H. Amesz, MSc
collection DOAJ
description Background: This study investigated oxygen handling of human hearts donated after circulatory death (DCD) on normothermic ex-situ heart perfusion (ESHP) and evaluated oxygen handling markers as adjuncts to cardiac viability assessment. Methods: This single-center retrospective study included human DCD heart transplantation procedures using ESHP. Lactate concentrations, blood gas, myocardial oxygen consumption (MVO2), delivery (MDO2), and extraction (MEO2), coronary blood flow (CBF), coronary vascular resistance (CVR), and adenosine infusion were reported over time. Correlation between parameters was assessed, and statistical testing compared patients who did and did not require extracorporeal membrane oxygenation (ECMO) support after transplantation. Results: Lactate concentrations decreased during ESHP in all transplanted hearts (n = 25) and increased in 1 rejected heart. Arterial partial pressure of oxygen (PO2) was 75.2 ± 2.9 kPa, with an arteriovenous ΔPO2 of 44.8 ± 10.4 kPa. Oxygen saturation was 100% in most arterial and venous samples. Average MVO2 was 2.7 ± 0.6 ml/min/100 g myocardium, MDO2 98.5 ± 20.4 ml/min, and MEO2 8.6 ± 1.8%. Average CVR was 0.025 ± 0.006 mm Hg min/ml/100 g and increased over time. ΔPO2 correlated strongly with MVO2 (R = 0.797, p < 0.001) and lactate trend (R = 0.799, p < 0.001) in transplanted hearts, without differences compared to the rejected heart with increasing lactate. Adenosine infusion on ESHP was significantly higher in patients requiring ECMO post-transplantation vs non-ECMO cases (11.7 (4.5-21.0) vs 2.2 (1.5-6.7) ml/h, p = 0.039). Conclusions: Hearts on normothermic ESHP receive excessive MDO2, due to high PO2 and CBF, while the MVO2 is relatively low. Thus, CBF and PO2 can potentially be lowered. Furthermore, ΔPO2 could serve as additional marker of metabolic function under these hyperoxic circumstances. The adenosine infusion rate might predict post-transplantation ECMO requirement.
format Article
id doaj-art-9ea7165bce94486e818ee49f3d40fc84
institution OA Journals
issn 2950-1334
language English
publishDate 2024-11-01
publisher Elsevier
record_format Article
series JHLT Open
spelling doaj-art-9ea7165bce94486e818ee49f3d40fc842025-08-20T02:12:42ZengElsevierJHLT Open2950-13342024-11-01610015910.1016/j.jhlto.2024.100159Myocardial oxygen handling and metabolic function of ex-situ perfused human hearts from circulatory death donorsJorik H. Amesz, MSc0Sanne J.J. Langmuur, BSc1Mark F.A. Bierhuizen, MD, LLM2Dwight Dumay, BSc3Pieter C. van de Woestijne, MD4Jelena Sjatskig, MD5Lisa E. Sluijter, MSc6Dirk J. Duncker, MD, PhD7Olivier C. Manintveld, MD, PhD8Yannick J.H.J. Taverne, MD, PhD, MSc9Translational Cardiothoracic Surgery Research Lab, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the NetherlandsTranslational Cardiothoracic Surgery Research Lab, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the NetherlandsTranslational Cardiothoracic Surgery Research Lab, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Cardiology, Erasmus University Medical Center, Rotterdam, the NetherlandsClinical Perfusion, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the NetherlandsDepartment of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the NetherlandsDepartment of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the NetherlandsClinical Perfusion, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the NetherlandsDivision of Experimental Cardiology, Department of Cardiology, Erasmus MC Cardiovascular Institute, Erasmus University Medical Center, Rotterdam, the NetherlandsErasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Cardiology, Erasmus University Medical Center, Rotterdam, the NetherlandsTranslational Cardiothoracic Surgery Research Lab, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; Department of Cardiothoracic Surgery, Erasmus University Medical Center, Rotterdam, the Netherlands; Erasmus MC Transplant Institute, Erasmus University Medical Center, Rotterdam, the Netherlands; Corresponding author: Yannick J.H.J. Taverne, MD, PhD, MSc, Department of Cardiothoracic Surgery, Erasmus University Medical Center, Doctor Molewaterplein 40, 3015GD Rotterdam, the Netherlands.Background: This study investigated oxygen handling of human hearts donated after circulatory death (DCD) on normothermic ex-situ heart perfusion (ESHP) and evaluated oxygen handling markers as adjuncts to cardiac viability assessment. Methods: This single-center retrospective study included human DCD heart transplantation procedures using ESHP. Lactate concentrations, blood gas, myocardial oxygen consumption (MVO2), delivery (MDO2), and extraction (MEO2), coronary blood flow (CBF), coronary vascular resistance (CVR), and adenosine infusion were reported over time. Correlation between parameters was assessed, and statistical testing compared patients who did and did not require extracorporeal membrane oxygenation (ECMO) support after transplantation. Results: Lactate concentrations decreased during ESHP in all transplanted hearts (n = 25) and increased in 1 rejected heart. Arterial partial pressure of oxygen (PO2) was 75.2 ± 2.9 kPa, with an arteriovenous ΔPO2 of 44.8 ± 10.4 kPa. Oxygen saturation was 100% in most arterial and venous samples. Average MVO2 was 2.7 ± 0.6 ml/min/100 g myocardium, MDO2 98.5 ± 20.4 ml/min, and MEO2 8.6 ± 1.8%. Average CVR was 0.025 ± 0.006 mm Hg min/ml/100 g and increased over time. ΔPO2 correlated strongly with MVO2 (R = 0.797, p < 0.001) and lactate trend (R = 0.799, p < 0.001) in transplanted hearts, without differences compared to the rejected heart with increasing lactate. Adenosine infusion on ESHP was significantly higher in patients requiring ECMO post-transplantation vs non-ECMO cases (11.7 (4.5-21.0) vs 2.2 (1.5-6.7) ml/h, p = 0.039). Conclusions: Hearts on normothermic ESHP receive excessive MDO2, due to high PO2 and CBF, while the MVO2 is relatively low. Thus, CBF and PO2 can potentially be lowered. Furthermore, ΔPO2 could serve as additional marker of metabolic function under these hyperoxic circumstances. The adenosine infusion rate might predict post-transplantation ECMO requirement.http://www.sciencedirect.com/science/article/pii/S2950133424001083cardiac transplantationex-situ heart perfusiondonation after circulatory deathmyocardial oxygen consumptionnormothermic machine perfusion
spellingShingle Jorik H. Amesz, MSc
Sanne J.J. Langmuur, BSc
Mark F.A. Bierhuizen, MD, LLM
Dwight Dumay, BSc
Pieter C. van de Woestijne, MD
Jelena Sjatskig, MD
Lisa E. Sluijter, MSc
Dirk J. Duncker, MD, PhD
Olivier C. Manintveld, MD, PhD
Yannick J.H.J. Taverne, MD, PhD, MSc
Myocardial oxygen handling and metabolic function of ex-situ perfused human hearts from circulatory death donors
JHLT Open
cardiac transplantation
ex-situ heart perfusion
donation after circulatory death
myocardial oxygen consumption
normothermic machine perfusion
title Myocardial oxygen handling and metabolic function of ex-situ perfused human hearts from circulatory death donors
title_full Myocardial oxygen handling and metabolic function of ex-situ perfused human hearts from circulatory death donors
title_fullStr Myocardial oxygen handling and metabolic function of ex-situ perfused human hearts from circulatory death donors
title_full_unstemmed Myocardial oxygen handling and metabolic function of ex-situ perfused human hearts from circulatory death donors
title_short Myocardial oxygen handling and metabolic function of ex-situ perfused human hearts from circulatory death donors
title_sort myocardial oxygen handling and metabolic function of ex situ perfused human hearts from circulatory death donors
topic cardiac transplantation
ex-situ heart perfusion
donation after circulatory death
myocardial oxygen consumption
normothermic machine perfusion
url http://www.sciencedirect.com/science/article/pii/S2950133424001083
work_keys_str_mv AT jorikhameszmsc myocardialoxygenhandlingandmetabolicfunctionofexsituperfusedhumanheartsfromcirculatorydeathdonors
AT sannejjlangmuurbsc myocardialoxygenhandlingandmetabolicfunctionofexsituperfusedhumanheartsfromcirculatorydeathdonors
AT markfabierhuizenmdllm myocardialoxygenhandlingandmetabolicfunctionofexsituperfusedhumanheartsfromcirculatorydeathdonors
AT dwightdumaybsc myocardialoxygenhandlingandmetabolicfunctionofexsituperfusedhumanheartsfromcirculatorydeathdonors
AT pietercvandewoestijnemd myocardialoxygenhandlingandmetabolicfunctionofexsituperfusedhumanheartsfromcirculatorydeathdonors
AT jelenasjatskigmd myocardialoxygenhandlingandmetabolicfunctionofexsituperfusedhumanheartsfromcirculatorydeathdonors
AT lisaesluijtermsc myocardialoxygenhandlingandmetabolicfunctionofexsituperfusedhumanheartsfromcirculatorydeathdonors
AT dirkjdunckermdphd myocardialoxygenhandlingandmetabolicfunctionofexsituperfusedhumanheartsfromcirculatorydeathdonors
AT oliviercmanintveldmdphd myocardialoxygenhandlingandmetabolicfunctionofexsituperfusedhumanheartsfromcirculatorydeathdonors
AT yannickjhjtavernemdphdmsc myocardialoxygenhandlingandmetabolicfunctionofexsituperfusedhumanheartsfromcirculatorydeathdonors